Copenhagen, Denmark; June 4, 2014 – Genmab A/S (OMX: GEN), together with its subsidiary, Genmab B.V., announced today a research collaboration with an undisclosed Biotechnology company which would use and evaluate Genmab’s proprietary antibody technologies, the DuoBody and HexaBody platforms.